Literature DB >> 28735817

Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Yu-Hsuan Lin1, Brittany E Jewell2, Julian Gingold3, Linchao Lu4, Ruiying Zhao5, Lisa L Wang4, Dung-Fang Lee6.   

Abstract

Rare hereditary disorders provide unequivocal evidence of the importance of genes in human disease pathogenesis. Familial syndromes that predispose to osteosarcomagenesis are invaluable in understanding the underlying genetics of this malignancy. Recently, patient-derived induced pluripotent stem cells (iPSCs) have been successfully utilized to model Li-Fraumeni syndrome (LFS)-associated bone malignancy, demonstrating that iPSCs can serve as an in vitro disease model to elucidate osteosarcoma etiology. We provide here an overview of osteosarcoma predisposition syndromes and review recently established iPSC disease models for these familial syndromes. Merging molecular information gathered from these models with the current knowledge of osteosarcoma biology will help us to gain a deeper understanding of the pathological mechanisms underlying osteosarcomagenesis and will potentially aid in the development of future patient therapies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer etiology; familial cancer syndrome; induced pluripotent stem cell; osteosarcoma

Mesh:

Year:  2017        PMID: 28735817      PMCID: PMC5558609          DOI: 10.1016/j.molmed.2017.06.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  165 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.

Authors:  Ruipeng Song; Ke Tian; Weidong Wang; Limin Wang
Journal:  Int J Surg       Date:  2015-04-30       Impact factor: 6.071

Review 3.  Induced Pluripotent Stem Cells Meet Genome Editing.

Authors:  Dirk Hockemeyer; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2016-05-05       Impact factor: 24.633

4.  Generation of induced pluripotent stem cells (iPSCs) from a retinoblastoma patient carrying a c.2663G>A mutation in RB1 gene.

Authors:  Sicong Zeng; Lvjun Liu; Qi Ouyang; Yan Zhao; Ge Lin; Liang Hu; Wen Li
Journal:  Stem Cell Res       Date:  2016-08-28       Impact factor: 2.020

5.  Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome.

Authors:  Lisa L Wang; Anu Gannavarapu; Claudia A Kozinetz; Moise L Levy; Richard A Lewis; Murali M Chintagumpala; Ramon Ruiz-Maldanado; Jose Contreras-Ruiz; Christopher Cunniff; Robert P Erickson; Dorit Lev; Maureen Rogers; Elaine H Zackai; Sharon E Plon
Journal:  J Natl Cancer Inst       Date:  2003-05-07       Impact factor: 13.506

Review 6.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

7.  The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.

Authors:  T Quist; H Jin; J-F Zhu; K Smith-Fry; M R Capecchi; K B Jones
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

8.  Altered translation of GATA1 in Diamond-Blackfan anemia.

Authors:  Leif S Ludwig; Hanna T Gazda; Jennifer C Eng; Stephen W Eichhorn; Prathapan Thiru; Roxanne Ghazvinian; Tracy I George; Jason R Gotlib; Alan H Beggs; Colin A Sieff; Harvey F Lodish; Eric S Lander; Vijay G Sankaran
Journal:  Nat Med       Date:  2014-06-22       Impact factor: 53.440

9.  The DNA helicase recql4 is required for normal osteoblast expansion and osteosarcoma formation.

Authors:  Alvin J M Ng; Mannu K Walia; Monique F Smeets; Anthony J Mutsaers; Natalie A Sims; Louise E Purton; Nicole C Walsh; T John Martin; Carl R Walkley
Journal:  PLoS Genet       Date:  2015-04-10       Impact factor: 5.917

10.  CDK1 phosphorylates WRN at collapsed replication forks.

Authors:  Valentina Palermo; Sara Rinalducci; Massimo Sanchez; Francesca Grillini; Joshua A Sommers; Robert M Brosh; Lello Zolla; Annapaola Franchitto; Pietro Pichierri
Journal:  Nat Commun       Date:  2016-09-16       Impact factor: 14.919

View more
  60 in total

1.  Extracellular vesicles from osteosarcoma cell lines contain miRNAs associated with cell adhesion and apoptosis.

Authors:  Sofía Jerez; Héctor Araya; Daniel Hevia; Carlos E Irarrázaval; Roman Thaler; Andre J van Wijnen; Mario Galindo
Journal:  Gene       Date:  2019-06-06       Impact factor: 3.688

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

3.  FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.

Authors:  Hanjun Li; Xiuguo Han; Shengbing Yang; Yongjie Wang; Yang Dong; Tingting Tang
Journal:  Oncogene       Date:  2021-03-14       Impact factor: 9.867

4.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

5.  Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.

Authors:  Ruoji Zhou; An Xu; Jian Tu; Mo Liu; Julian A Gingold; Ruiying Zhao; Dung-Fang Lee
Journal:  J Vis Exp       Date:  2018-06-13       Impact factor: 1.355

Review 6.  Exosomes in osteosarcoma research and preclinical practice.

Authors:  Xiao-Bo Zhang; Rui-Hao Zhang; Xin Su; Jin Qi; Yi-Cun Hu; Jin-Tao Shi; Kai Zhang; Ke-Ping Wang; Hai-Yu Zhou
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 7.  Cancer in a dish: progress using stem cells as a platform for cancer research.

Authors:  Mo Liu; Jian Tu; Julian A Gingold; Celine Shuet Lin Kong; Dung-Fang Lee
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

8.  Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.

Authors:  Changhui Li; Shouyun Zhang; Tongguo Qiu; Yuanji Wang; David M Ricketts; Chao Qi
Journal:  Cancer Biol Ther       Date:  2018-11-29       Impact factor: 4.742

9.  CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.

Authors:  Qinglian Tang; Jinchang Lu; Changye Zou; Yang Shao; Yan Chen; Swami Narala; Hui Fang; Huaiyuan Xu; Jin Wang; Jingnan Shen; Rama Khokha
Journal:  Oncogene       Date:  2018-04-03       Impact factor: 9.867

10.  Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.

Authors:  Huensuk Kim; Seungyeul Yoo; Ruoji Zhou; An Xu; Jeffrey M Bernitz; Ye Yuan; Andreia M Gomes; Michael G Daniel; Jie Su; Elizabeth G Demicco; Jun Zhu; Kateri A Moore; Dung-Fang Lee; Ihor R Lemischka; Christoph Schaniel
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.